SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, today commenced the prepayment and initial delivery of approximately 103 million shares under its previously announced $25 billion accelerated share repurchase ("ASR†) agreements that it entered into on March 11, 2026 with certain financial institutions. This transaction, the largest ASR in history, represents the immediate execution of half of the $50 billion aggregate Share Repurchase Program authorized by Salesfor. ...

Core Viewpoint - Sallie Mae has announced a $200 million accelerated share repurchase agreement with Goldman Sachs, part of a broader $500 million share repurchase program authorized by its Board of Directors [1] Group 1: Share Repurchase Agreement - The company has entered into a $200 million accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC [1] - The ASR is part of a $500 million share repurchase program that was authorized by Sallie Mae's Board of Directors [1] - The share repurchase program is effective from January 22, 2026 [1]

Core Viewpoint - Verisk Analytics, Inc. has announced accelerated share repurchase agreements totaling $1.5 billion to repurchase its common stock, enhancing shareholder value and demonstrating confidence in its financial position [1][2]. Share Repurchase Details - The company will repurchase an aggregate of $1.5 billion of its common stock through agreements with HSBC Bank USA and Wells Fargo Bank [1]. - An initial delivery of approximately 7.0 million shares is expected at the inception of the ASR Agreements, with the final number of shares to be determined based on the daily volume-weighted average share price during the calculation period [2]. - The final settlement of the transactions is anticipated to occur by the end of the third fiscal quarter of 2026, with specific settlement dates determined by the ASR Counterparties [3]. Future Share Repurchases - The company may continue to repurchase shares in the open market as market conditions allow, indicating a flexible approach to capital management [4]. Company Overview - Verisk is a leading strategic data analytics and technology partner for the global insurance industry, focusing on improving operational efficiency, underwriting, claims outcomes, and addressing global risks [5].

Core Insights - Soleno Therapeutics has authorized a $100 million share repurchase and entered into an Accelerated Share Repurchase Agreement with Jefferies LLC [1][2] - The company achieved profitability in Q3 2025 and believes its future cash generation potential is undervalued by the market [2] Financial Actions - The initial payment under the ASR agreement will be $100 million, with an initial delivery of approximately 1,511,553 shares based on the closing price on November 10, 2025 [2] - The final number of shares repurchased will depend on the average volume-weighted price during the transaction period and will be subject to adjustments [2] Product Information - Soleno's first commercial product, VYKAT XR, is an oral treatment for hyperphagia in patients with Prader-Willi syndrome, targeting both adults and children aged 4 and older [4]

Core Insights - Edwards Lifesciences is set to announce its operating results for Q3 2025 on October 30, 2025, followed by a conference call to discuss these results [1][2]. Company Overview - Edwards Lifesciences is recognized as a leading global company in structural heart innovation, focusing on improving patient lives through advanced technologies and partnerships with healthcare stakeholders [3]. Financial Activities - The company has executed an accelerated share repurchase agreement to buy back $500 million of its common stock, bringing the total repurchased shares in 2025 to over $800 million [8]. Regulatory Developments - The U.S. Federal Trade Commission (FTC) has moved to block Edwards Lifesciences' proposed acquisition of JenaValve Technology, which the company believes will limit treatment options for patients with aortic regurgitation [9].

Core Points - Marvell Technology, Inc. has authorized a new $5 billion stock repurchase program, building on its commitment to return capital to stockholders [1][2] - The company has approximately $2 billion remaining under its prior repurchase authorization and has repurchased $300 million of common stock in the current quarter [2] - Marvell has entered into an accelerated share repurchase (ASR) agreement to repurchase an additional $1 billion of its common stock [2][3] - CEO Matt Murphy emphasized the company's confidence in its business and stock value, highlighting sustained revenue and cash flow growth [3] Financial Overview - The new stock repurchase program is part of Marvell's strategy to enhance shareholder value [1][2] - The total amount repurchased in the current quarter, including the ASR, amounts to $1.3 billion [2] Upcoming Events - Marvell's Chairman and CEO will participate in a fireside chat hosted by JP Morgan on September 24, 2025, at 10 AM Pacific Time [3][4]

Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].